Ireland
--:--IST
Latest
Clinical Trials in Turkey / NCT06951022
Active, not recruiting Not applicable

The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women

NCT06951022 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-01-30
Last updated
2025-04-30

Condition(s) studied

Urinary Incontinence (UI)Postmenopause

Investigational drug(s) / intervention(s)

Sujok therapy

Sujok therapy: Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.

Study summary

This study aims to investigate the effect of Su Jok therapy, a complementary medicine practice, on urinary incontinence and quality of life among postmenopausal women. A total of 120 participants will be included in the study, with 60 in the intervention group and 60 in the control group. Participants in the intervention group will receive Su Jok seed therapy applied to the hand reflex points corresponding to the bladder. The therapy will be administered by the researcher and then taught to the participants, who will continue the application for 15 days. Assessments will be conducted at baseline, day 15, and day 30 using validated questionnaires.

Eligibility

Sex
FEMALE
Min age
—
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: Women under 65 years of age in the postmenopausal period, Literate, No speech or communication impairment Exclusion Criteria: Use of diuretics Presence of nephrotic syndrome Diagnosis of diabetes or hypertension Symptoms of urinary tract infection Diagnosis of psychiatric illness History of urinary tract surgery Diagnosed urinary prolapse Failure to complete the intervention

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Inonu University Battalgazi Malatya

More Inonu University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06951022 on ClinicalTrials.gov ↗ ← All trials in Turkey